192 related articles for article (PubMed ID: 38798691)
1. Enhanced Complement Expression in the Tumor Microenvironment Following Neoadjuvant Therapy: Implications for Immunomodulation and Survival in Pancreatic Ductal Adenocarcinoma.
Zhang X; Lan R; Liu Y; Pillarisetty VG; Li D; Zhao CL; Sarkar SA; Liu W; Hanna I; Gupta M; Hajdu C; Melamed J; Shusterman M; Widmer J; Allendorf J; Liu YZ
Res Sq; 2024 May; ():. PubMed ID: 38798691
[TBL] [Abstract][Full Text] [Related]
2. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression.
Chen K; Wang Q; Li M; Guo H; Liu W; Wang F; Tian X; Yang Y
EBioMedicine; 2021 Apr; 66():103315. PubMed ID: 33819739
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
4. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5.
Nakajima K; Ino Y; Naito C; Nara S; Shimasaki M; Ishimoto U; Iwasaki T; Doi N; Esaki M; Kishi Y; Shimada K; Hiraoka N
Br J Cancer; 2022 Mar; 126(4):628-639. PubMed ID: 34824448
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
6. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
7. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
8. Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma.
Liu T; Chen Z; Chen W; Evans R; Xu J; Reeves ME; de Vera ME; Wang C
Precis Clin Med; 2023 Mar; 6(1):pbad004. PubMed ID: 37007745
[TBL] [Abstract][Full Text] [Related]
9. Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.
Taherian M; Wang H
Chin Clin Oncol; 2022 Jun; 11(3):21. PubMed ID: 35726190
[TBL] [Abstract][Full Text] [Related]
10. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma.
Zhang Y; Huang ZX; Song B
World J Gastroenterol; 2021 Jun; 27(22):3037-3049. PubMed ID: 34168406
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract][Full Text] [Related]
12. Multiphasic Heterogeneity of Fibroblasts in the Microenvironment of Pancreatic Ductal Adenocarcinoma: Dissection and the Sum of the Dynamics.
Ijichi H
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230803
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells associate with epithelial cells in the pancreatic ductal adenocarcinoma tumor microenvironment.
Malchiodi ZX; Suter RK; Deshpande A; Peran I; Harris BT; Duttargi A; Chien MJ; Hariharan S; Wetherill L; Jablonski SA; Ho WJ; Fertig EJ; Weiner LM
bioRxiv; 2024 May; ():. PubMed ID: 38853982
[TBL] [Abstract][Full Text] [Related]
14. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
16. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract][Full Text] [Related]
17. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
[TBL] [Abstract][Full Text] [Related]
18. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
[TBL] [Abstract][Full Text] [Related]
19. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer.
Cui M; Shoucair S; Liao Q; Qiu X; Kinny-Köster B; Habib JR; Ghabi EM; Wang J; Shin EJ; Leng SX; Ali SZ; Thompson ED; Zimmerman JW; Shubert CR; Lafaro KJ; Burkhart RA; Burns WR; Zheng L; He J; Zhao Y; Wolfgang CL; Yu J
Int J Surg; 2023 Feb; 109(2):99-106. PubMed ID: 36799816
[TBL] [Abstract][Full Text] [Related]
20. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
Stouten I; van Montfoort N; Hawinkels LJAC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
